NEWS
NHS SLASHES TESTS AND CHECKS WAITS TO A FIVE-YEAR LOW
Together with the government, the NHS published the elective care reform plan in January, setting out how the NHS will reform care for patients and meet the 18 week standard by March 2029.
NHS staff have more than halved the average wait for tests and checks since the height of the pandemic as the waiting list continues to fall, new data shows.
Patients were waiting an average of 17 days for tests and checks in January – 43 days less than at the height of the pandemic( May 2020).
Average waits for tests are now the lowest since 2.1 weeks in February 2020.
NHS teams delivered more than 2.5 million checks in January, up almost a quarter( 23 %) on 2.05 million in January 2019 and 5 % higher than the same month last year( 2.4 million in January 2024).
The total waiting list in January fell for the fifth month in a row by 35,000 from 7.46 million to 7.43 million, meaning it has now fallen by 193,000 since July 2024. The estimated number of patients waiting in January was 6.25 million.
ROCHE ANNOUNCES LAUNCH OF ROCHE GENENTECH INNOVATION CENTER BOSTON BASED AT HARVARD’ S ENTERPRISE RESEARCH CAMPUS IN ALLSTON
Roche has announced the launch of the Roche Genentech Innovation Center Boston at Harvard’ s
Enterprise Research Campus in Allston which will further strengthen the long-standing partnership in areas such as disease biology, engineering and Artificial Intelligence / Machine Learning.
The Roche Genentech Innovation Center Boston will serve as Roche’ s Cardiovascular, Renal and Metabolism( CVRM) hub, establishing a significant end-to-end R & D presence in CVRM. It will also support some of Roche’ s and Genentech’ s efforts in AI and data science to accelerate drug discovery and development.
The laboratories will be equipped for advanced research, and over time the centre could employ up to 500 people.
Roche CEO, Thomas Schinecker, said:“ Our new innovation centre builds upon our long-standing collaboration with Harvard and enables us to leverage the exceptional talent in the Boston area. By investing in a new Cardiovascular, Renal and Metabolism centre of excellence, along with data science and AI capabilities at this strategic location, we aim to accelerate Roche’ s and Genentech’ s research efforts and leverage the Boston innovation ecosystem. Roche has a significant presence in the US and this new centre is one of a number of research and manufacturing investments that Roche is making in the US through Genentech and Diagnostics.”
10 www. intelligenthealth. tech